A brain scanner based on differential near-infrared (NIR) energy is getting a healthy push forward with a $3.7 million, four-year contract with the U.S. Marine Corps and Navy for the development of diagnostic imaging for traumatic brain injury and hematoma, makers InfraScan announced Oct. 1.

Anti-angiogenesis drugs have been making waves as treatments for some cancers. Researchers have been developing new biomarkers to map the progress of these therapies, including those that target integrin expression. However, a new study published online yesterday in the Journal of Nuclear Medicine indicates that integrin expression imaging may not provide a mirror image of the impact of peptide therapy as it occurs.

Yet another risk factor for neurodegenerative disease has cropped up in recent studies: Worry among older women. Research conducted at the University of Gothenburg in Sweden provided a score on the scale of neuroticism for 800 women in mid-life and evaluated any potential links to Alzheimer's. Those who peaked on the anxiety scale were two times as likely to develop the disease.

A first-in-human study of (D)-18F-fluoromethyltyrosine (D-18F-FMT), a tyrosine derivative, is being evaluated for diagnostic imaging of non-small cell lung cancer (NSCLC) as well as head and neck squamous cell cancers (HNSCC). Results show that it could provide some differentiation in a space dominated by FDG, according to a study published Sept. 25 in the Journal of Nuclear Medicine.

As the healthcare community awaits the decision from the Centers for Medicare & Medicaid Services (CMS) on whether low-dose CT screening for lung cancer will be covered for Medicare beneficiaries, two editorials published in the Sept. 24 issue of JAMA recommended ways to cautiously move forward with screening.

An analysis of genetic biomarkers from Genetic Engineering & Biotechnology explains the differences between predictive and prognostic characteristics and provides a perspective on the current landscape of research and development for a number of key assays.

Carestream’s continuous innovation in CR technology has enabled thousands of facilities across the globe to convert to high-quality digital imaging with CARESTREAM Vita CR and Point-of-Care systems.

A prospective clinical evaluation at St. Elizabeth Healthcare showed that Toshiba America Medical Systems, Inc.’s Smart Fusion ultrasound technology gives clinicians a worry-free experience, delivering safer and more accurate guidance for liver and kidney lesion biopsies.